Pertussis Conference National Institutes of Health, Acellular Pertussis Vaccine Trials: results and impact on U. S. Public Health. 3–5 June 1996 National Institutes of Health; Washington, DC, USA:
WHO/IABS/NIBSC International Meeting on the Control and Standardisation of Acellular Pertussis Vaccines. 26–27 Sept Potters Bar; UK: Dev Biol Stand1997; 89 (in press)
IbsenP. H. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine1996; 14:359–368
SchmittH. J. Results of a household contact protective efficacy study. Presented at: Caring for the new generation. Conference; Sorrento; Italy:6–7 April 1995 Abstract (p. 37)
ZeppF.,
KnufM.,
HabermehlP. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun1996; 64:4078–4084
BarnardA.,
MahonB. P.,
WatkinsJ.,
RedheadK.,
MillsK. H. G. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology1996; 87:372–380
GustafssonL.,
HallanderH. O.,
OlinP.,
ReizensteinE.,
StorsaeterJ. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med1996; 334:349–355
GrecoD.,
SalmasoS.,
MastrantonioP. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med1996; 334:341–348
SatoY.,
SatoH. Animal models in pertussis. In
WardlawA. C.,
PartonR.
(eds) Pathogenesis and immunity in pertussis Chichester: John Wiley and Sons; 1988309–325